Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000313 · ClinicalTrials.gov registry record · Phase 1
Predictive Values of Serotonergic Alterations for Outcome - 2
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00000313: Clinical Trial Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000313 is a Phase 1 study that was terminated before completion, run by National Institute on Drug Abuse (NIDA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000313, a Phase 1 study, was terminated before completion, sponsored by National Institute on Drug Abuse (NIDA).
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to evaluate the predictive value of serotonergic alterations for outcome.
Interventions
- DRUG Fenfluramine
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Why NCT00000313 stopped before completion
NCT00000313 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Fenfluramine is the first listed.
NCT00000313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000313 about?
NCT00000313 is a clinical study titled "Predictive Values of Serotonergic Alterations for Outcome - 2". The purpose of this study is to evaluate the predictive value of serotonergic alterations for outcome.
What is the current status of trial NCT00000313?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00000313?
The interventions under investigation include: Fenfluramine (DRUG).
Who is sponsoring clinical trial NCT00000313?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.